Is endoscopic surveillance for non-dysplastic Barrett's esophagus cost-effective? Review of economic evaluations

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 2, 2011, Pages 247-254

  Hirst, Nicholas G ^a   Gordon, Louisa G ^a   Whiteman, David C ^a   Watson, David I ^c   Barendregt, Jan J ^b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

Barrett esophagus; Cost benefit analysis; Esophageal neoplasms; Population surveillance

Indexed keywords

BARRETT ESOPHAGUS; CANCER RECURRENCE; COST EFFECTIVENESS ANALYSIS; GASTROINTESTINAL ENDOSCOPY; HEALTH ECONOMICS; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

EID: 78851469406     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06506.x     Document Type: Review

References (51)

1. Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin. Gastroenterol. Hepatol. 2006; 4: 566-72.
2. Stavrou EP, McElroy HJ, Baker DF, Smith G, Bishop JF. Adenocarcinoma of the oesophagus: incidence and survival rates in New South Wales, 1972-2005. Med. J. Aust. 2009; 191: 310-14.
3. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J. Natl. Cancer Inst. 2008; 100: 1184-7.
4. Pandeya N, Williams G, Green AC, Webb PM, Whiteman DC. Alcohol consumption and the risks of adenocarcinoma and squamous cell carcinoma of the esophagus. Gastroenterology 2009; 136: 1215-24.
5. Martiniuk A, Lee CM, Woodward M, Huxley R. Burden of lung cancer deaths due to smoking for men and women in the WHO western pacific and South East Asian regions. Asian Pac. J. Cancer Prev. 2010; 11: 67-72.
6. Whiteman DC, Sadeghi S, Pandeya N etal. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut 2008; 57: 173-80.
7. Cheng MH. Asia-Pacific faces diabetes challenge. Lancet 2010; 375: 2207-10.
8. Neale RE, Doecke JD, Pandeya N etal. Does type 2 diabetes influence the risk of oesophageal adenocarcinoma? Br. J. Cancer 2009; 100: 795-8.
9. Epari K, Cade RJ. Oesophagectomy for tumours and dysplasia of the oesophagus and gastro-oesophageal junction. ANZ J. Surg. 2009; 79: 251-7.
10. Rice TW, Blackstone EH, Rybicki LA etal. Refining esophageal cancer staging. J. Thorac. Cardiovasc. Surg. 2003; 125: 1103-13.
11. Williams VA, Watson TJ, Herbella FA etal. Esophagectomy for high grade dysplasia is safe, curative, and results in good alimentary outcome. J. Gastrointest. Surg. 2007; 11: 1589-97.
12. Rubenstein JH, Sonnenberg A, Davis J, McMahon L, Inadomi JM. Effect of a prior endoscopy on outcomes of esophageal adenocarcinoma among United States veterans. Gastrointest. Endosc. 2008; 68: 849-55.
13. Cooper GS, Kou TD, Chak A. Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: a population-based study with temporal trends. Am. J. Gastroenterol. 2009; 104: 1356-62.
14. Quera R, O'Sullivan K, Quigley EM. Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma? Endoscopy 2006; 38: 162-9.
15. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am. J. Gastroenterol. 2008; 103: 788-97.
16. Shaheen NJ, Richter JE. Barrett's oesophagus. Lancet 2009; 373: 850-61.
17. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96: 1249-56.
18. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland clinic Barrett's esophagus registry. Am. J. Gastroenterol. 1999; 94: 2037-42.
19. Murray L, Watson P, Johnston B, Sloan J, Mainie IM, Gavin A. Risk of adenocarcinoma in Barrett's oesophagus: population based study. BMJ 2003; 327: 534-5.
20. Basu KK, Pick B, de Caestecker JS. Audit of a Barrett's epithelium surveillance database. Eur. J. Gastroenterol. Hepatol. 2004; 16: 171-5.
21. Caygill CP, Reed PI, Hill MJ, Watson A. An initial comparison of nine centres registering patients with the UK national Barrett's oesophagus registry (UKBOR). Eur. J. Cancer Prev. 1999; 8: 539-42.
22. Shaheen N, Ransohoff DF. Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review. JAMA 2002; 287: 1972-81.
23. Amamra N, Touzet S, Colin C, Ponchon T. Current practice compared with the international guidelines: endoscopic surveillance of Barrett's esophagus. J. Eval. Clin. Pract. 2007; 13: 789-94.
24. Abrams JA, Kapel RC, Lindberg GM etal. Adherence to biopsy guidelines for Barrett's esophagus surveillance in the community setting in the United States. Clin. Gastroenterol. Hepatol. 2009; 13: 13.
25. Meining A, Ott R, Becker I etal. The Munich Barrett follow up study: suspicion of Barrett's oesophagus based on either endoscopy or histology only-what is the clinical significance? Gut 2004; 53: 1402-7.
26. Alikhan M, Rex D, Khan A, Rahmani E, Cummings O, Ulbright TM. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest. Endosc. 1999; 50: 23-6.
27. Kim SL, Waring JP, Spechler SJ etal. Diagnostic inconsistencies in Barrett's esophagus. Department of veterans affairs gastroesophageal reflux study group. Gastroenterology 1994; 107: 945-9.
28. Macdonald CE, Wicks AC, Playford RJ. Final results from 10year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ 2000; 321: 1252-5.
29. Aldulaimi DM, Cox M, Nwokolo CU, Loft DE. Barrett's surveillance is worthwhile and detects curable cancers. A prospective cohort study addressing cancer incidence, treatment outcome and survival. Eur. J. Gastroenterol. Hepatol. 2005; 17: 943-50.
30. Weinstein MC, O'Brien BJ, Hornberger J etal. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR task force on good research practices-modeling studies. Value Health 2003; 6: 9-17.
31. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Br. Med. J. 2009; 339: 332-6.
32. Anderson R. Systematic reviews of economic evaluations: utility or futility? Health Econ. 2009; 20: 20.
33. Pignone M, Saha S, Hoerger T, Lohr KN, Teutsch S, Mandelblatt J. Challenges in systematic reviews of economic analyses. Ann. Intern. Med. 2005; 142: 1073-9.
34. Drummond M, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press, 2005.
35. Briggs AH, Claxton K, Sculpher MJ. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press, 2006.
36. Somerville M, Garside R, Pitt M, Stein K. Surveillance of Barrett's oesophagus: is it worthwhile? Eur. J. Cancer 2008; 44: 588-99.
37. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann. Intern. Med. 2003; 138: 176-86.
38. Inadomi JM, Somsouk M, Madanick RD, Thomas JP, Shaheen NJ. A cost-utility analysis of ablative therapy for Barrett's esophagus. Gastroenterology 2009; 136: 2101-14.
39. Sonnenberg A, Fennerty MB. Medical decision analysis of chemoprevention against esophageal adenocarcinoma. Gastroenterology 2003; 124: 1758-66.
40. Sonnenberg A, Soni A, Sampliner RE. Medical decision analysis of endoscopic surveillance of Barrett's oesophagus to prevent oesophageal adenocarcinoma. Aliment. Pharmacol. Ther. 2002; 16: 41-50.
41. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am. J. Gastroenterol. 1999; 94: 2043-53.
42. Das A, Wells C, Kim HJ, Fleischer DE, Crowell MD, Sharma VK. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett's esophagus. Endoscopy 2009; 41: 400-8.
43. Garside R, Pitt M, Somerville M, Stein K, Price A, Gilbert N. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling. Health Technol. Assess. 2006; 10: 1-158.
44. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000; 119: 333-8.
45. Provenzale D, Kemp JA, Arora S, Wong JB. A guide for surveillance of patients with Barrett's esophagus. Am. J. Gastroenterol. 1994; 89: 670-80.
46. Bytzer P, Christensen PB, Damkier P, Vinding K, Seersholm N. Adenocarcinoma of the esophagus and Barrett's esophagus: a population-based study. Am. J. Gastroenterol. 1999; 94: 86-91.
47. Iftikhar SY, James PD, Steele RJ, Hardcastle JD, Atkinson M. Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut 1992; 33: 1155-8.
48. Zhang X, Watson DI, Jamieson GG, Lally C, Bessell JR, Devitt PG. Outcome of oesophagectomy for adenocarcinoma of the oesophagus and oesophago-gastric junction. Aust. N. Z. J. Surg. 2005; 75: 513-9.
49. Wolfsen HC. New technologies for imaging of Barrett's esophagus. Surg. Oncol. Clin. N. Am. 2009; 18: 487-502.
50. Bampton P, Schloithe A, Bull J, Padbury R, Watson D. Improving surveillance for Barrett's oesophagus. Br. Med. J. 2006; 332: 1320-3.
51. Shaheen N, Sharma P, Overholt BF etal. Radiofrequency ablation in Barrett's esophagus with dysplasia. N. Engl. J. Med. 2009; 360: 2277-88.